TOP > 外国特許検索 > METHOD FOR PRODUCING PANCREATIC ENDOCRINE CELLS, AND TRANSDIFFERENTIATION AGENT

METHOD FOR PRODUCING PANCREATIC ENDOCRINE CELLS, AND TRANSDIFFERENTIATION AGENT NEW

外国特許コード F170009294
整理番号 S2015-1882-C0
掲載日 2017年11月21日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2016JP082095
国際公開番号 WO 2017073740
国際出願日 平成28年10月28日(2016.10.28)
国際公開日 平成29年5月4日(2017.5.4)
優先権データ
  • 特願2015-212563 (2015.10.29) JP
発明の名称 (英語) METHOD FOR PRODUCING PANCREATIC ENDOCRINE CELLS, AND TRANSDIFFERENTIATION AGENT NEW
発明の概要(英語) A method for producing pancreatic endocrine cells, said method comprising an introduction step in which any of the following genes or gene products are introduced into somatic cells: (A) a mutant GLIS1 gene or gene product thereof having at least 85% sequence identity with the nucleic acid sequence represented by SEQ. ID No. 1 or 2, a Neurogenin-3 gene or gene product thereof, a Pdx1 gene or gene product thereof, and a MafA gene or gene product thereof; (B) a mutant GLIS1 gene or gene product thereof having at least 85% sequence identity with the nucleic acid sequence represented by SEQ. ID No. 1 or 2, a Neurogenin-3 gene or gene product thereof, and a Pdx1 gene or gene product thereof; (C) a GLIS1 gene or gene product thereof, a Neurogenin-3 gene or gene product thereof, a Pdx1 gene or gene product thereof, and a MafA gene or gene product thereof; and (D) a mutant GLIS1 gene or gene product thereof having at least 85% sequence identity with the nucleic acid sequence represented by SEQ. ID No. 1 or 2, a Neurogenin-3 gene or gene product thereof, and a MafA gene or gene product thereof.
特許請求の範囲(英語) [claim1]
1. Description below production method of the *** incretion cell which features that the introduction process where (D) introduces each gene or that gene product into the somatic cell from (A) is included.
(A) SEQ ID NO: The mutation GLIS1 gene or that gene product which possesses the arrangement identity above base arranging and 85% where it is displayed with either 1 and 2, the Neurogenin3 gene or that gene product, the Pdx1 gene or that gene product, and the MafA gene or that gene product.
(B) SEQ ID NO: The mutation GLIS1 gene or that gene product which possesses the arrangement identity above base arranging and 85% where it is displayed with either 1 and 2, the Neurogenin3 gene or that gene product, and the Pdx1 gene or that gene product.
(C) GLIS1 gene or that gene product, Neurogenin3 gene or that gene product, Pdx1 gene or that gene product, and MafA gene or that gene product.
(D) SEQ ID NO: The mutation GLIS1 gene or that gene product which possesses the arrangement identity above base arranging and 85% where it is displayed with either 1 and 2, the Neurogenin3 gene or that gene product, and the MafA gene or that gene product.
[claim2]
2. Is introduced into the somatic cell with the aforementioned introduction process the description above which from (A) (D) no gene or that gene product, (A) the SEQ ID NO: The mutation GLIS1 gene or that gene product which possesses the arrangement identity above base arranging and 85% where it is displayed with either 1 and 2, the Neurogenin3 gene or that gene product, in the claim 1 which is the Pdx1 gene or that gene product, and the MafA gene or that gene product production method of the *** incretion cell of statement.
[claim3]
3. Is introduced into the somatic cell with the aforementioned introduction process the description above which from (A) (D) no gene or that gene product, (B) the SEQ ID NO: The mutation GLIS1 gene or that gene product which possesses the arrangement identity above base arranging and 85% where it is displayed with either 1 and 2, in the claim 1 which is the Neurogenin3 gene or that gene product, and the Pdx1 gene or that gene product production method of the *** incretion cell of statement.
[claim4]
4. The description above which is introduced into the somatic cell with the aforementioned introduction process from (A) (D) no gene or that gene product, (C) the GLIS1 gene or that gene product, the Neurogenin3 gene or that gene product, in the claim 1 which is the Pdx1 gene or that gene product, and the MafA gene or that gene product production method of the *** incretion cell of statement.
[claim5]
5. Is introduced into the somatic cell with the aforementioned introduction process the description above which from (A) (D) no gene or that gene product, (D) the SEQ ID NO: The mutation GLIS1 gene or that gene product which possesses the arrangement identity above base arranging and 85% where it is displayed with either 1 and 2, in the claim 1 which is the Neurogenin3 gene or that gene product, and the MafA gene or that gene product production method of the *** incretion cell of statement.
[claim6]
6. The aforementioned somatic cell, from the claim 1 which is either the tissue bud cell and the mesenchyme type trunk cell in either of 5 production method of the *** incretion cell of statement.
[claim7]
7. The *** incretion cell, from the claim 1 which is the I cell in either of 6 production method of the *** incretion cell of statement.
[claim8]
8. The somatic cell being the differentiation conversion medicine which it differentiates converts to the *** incretion cell,
Description below the differentiation conversion medicine which features that (D) includes each gene or that gene product from (A).
(A) SEQ ID NO: The mutation GLIS1 gene or that gene product which possesses the arrangement identity above base arranging and 85% where it is displayed with either 1 and 2, the Neurogenin3 gene or that gene product, the Pdx1 gene or that gene product, and the MafA gene or that gene product.
(B) SEQ ID NO: The mutation GLIS1 gene or that gene product which possesses the arrangement identity above base arranging and 85% where it is displayed with either 1 and 2, the Neurogenin3 gene or that gene product, and the Pdx1 gene or that gene product.
(C) GLIS1 gene or that gene product, Neurogenin3 gene or that gene product, Pdx1 gene or that gene product, and MafA gene or that gene product.
(D) SEQ ID NO: The mutation GLIS1 gene or that gene product which possesses the arrangement identity above base arranging and 85% where it is displayed with either 1 and 2, the Neurogenin3 gene or that gene product, and the MafA gene or that gene product.
[claim9]
9. From the description above (A) (D) no gene or that gene product, (A) SEQ ID NO: The mutation GLIS1 gene or that gene product which possesses the arrangement identity above base arranging and 85% where it is displayed with either 1 and 2, the Neurogenin3 gene or that gene product, in the claim 8 which is the Pdx1 gene or that gene product, and the MafA gene or that gene product the differentiation conversion medicine of statement.
[claim10]
10. From the description above (A) (D) no gene or that gene product, (B) SEQ ID NO: The mutation GLIS1 gene or that gene product which possesses the arrangement identity above base arranging and 85% where it is displayed with either 1 and 2, in the claim 8 which is the Neurogenin3 gene or that gene product, and the Pdx1 gene or that gene product the differentiation conversion medicine of statement.
[claim11]
11. The description above from (A) (D) no gene or that gene product, (C) the GLIS1 gene or that gene product, the Neurogenin3 gene or that gene product, in the claim 8 which is the Pdx1 gene or that gene product, and the MafA gene or that gene product the differentiation conversion medicine of statement.
[claim12]
12. From the description above (A) (D) no gene or that gene product, (D) SEQ ID NO: The mutation GLIS1 gene or that gene product which possesses the arrangement identity above base arranging and 85% where it is displayed with either 1 and 2, in the claim 8 which is the Neurogenin3 gene or that gene product, and the MafA gene or that gene product the differentiation conversion medicine of statement.
[claim13]
13. The aforementioned somatic cell, from the claim 8 which is either the tissue bud cell and the mesenchyme type trunk cell in either of 12 the differentiation conversion medicine of statement.
[claim14]
14. The *** incretion cell, from the claim 8 which is the I cell in either of 13 the differentiation conversion medicine of statement.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • SAITAMA MEDICAL UNIVERSITY
  • 発明者(英語)
  • MATSUMOTO MASAHITO
  • OKAZAKI YASUSHI
  • SUGAHARA IZUMI
国際特許分類(IPC)
指定国 (WO201773740)
National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DJ DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JP KE KG KN KP KR KW KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG

PAGE TOP

close
close
close
close
close
close